Importance of P-cadherin, β-catenin, and Wnt5a/Frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8606-8614

  Bachmann, Ingeborg M ^a   Straume, Oddbjørn ^a   Puntervoll, Hanne E ^a   Kalvenes, May Britt ^a   Akslen, Lars A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CADHERIN; CELL ADHESION MOLECULE; FRIZZLED PROTEIN; NERVE CELL ADHESION MOLECULE; NUCLEAR PROTEIN; P CADHERIN; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN; WNT5A PROTEIN;

ADULT; ARTICLE; BENIGN TUMOR; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; NEVUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; TISSUE MICROARRAY; TUMOR VOLUME;

BETA CATENIN; CADHERINS; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; DISEASE PROGRESSION; DOWN-REGULATION; FRIZZLED RECEPTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; NEVUS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROTRANSMITTER; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; WNT PROTEINS;

EID: 29344459785     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0011     Document Type: Article

References (53)

1. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003;94:575-81.
2. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002;34:255-68.
3. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003; 19:207-35.
4. Nishimura EK, Yoshida H, Kunisada T, Nishikawa SI. Regulation of E- and P-cadherin expression correlated with melanocyte migration and diversification. Dev Biol 1999;215:155-66.
5. Furukawa F, Fujii K, Horiguchi Y, et al. Roles of E- and P-cadherin in the human skin. Microsc Res Tech 1997; 38:343-52.
6. Navarro P, Ruco L, Dejana E. Differential localization of VE- and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. J Cell Biol 1998;140:1475-84.
7. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1:459-65.
8. Hsu MY, Wheelock MJ, Johnson KR, Herlyn M. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1996;1:188-94.
9. Krengel S, Groteluschen F, Bartsch S, Tronnier M. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression. J Cutan Pathol 2004; 31:1-7.
10. Sanders DS, Blessing K, Hassan GA, Bruton R, Marsden JR, Jankowski J. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. Mol Pathol 1999;52:151-7.
11. Tang A, Eller MS, Hara M, Yaar M, Hirohashi S, Gilchrest BA. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci 1994;107:983-92.
12. Akiyama T. Wnt/β-catenin signaling. Cytokine Growth Factor Rev 2000;11:273-82.
13. Morin PJ. β-Catenin signaling and cancer. BioEssays 1999;21:1021-30.
14. Rubinfeld B, Robbins P, EI-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-2.
15. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of β-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999;154:325-9.
16. Maelandsmo GM, Holm R, Nesland JM, Fodstad O, Florenes VA. Reduced β-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 2003;9:3383-8.
17. Kageshita T, Hamby CV, Ishihara T, Matsumoto K, Saida T, Ono T. Loss of β-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 2001;145:210-6.
18. Carr KM, Bittner M. Trent JM. Gene-expression profiling in human cutaneous melanoma. Oncogene 2003;22:3076-80.
19. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
20. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002;1:279-88.
21. Pham K, Milovanovic T, Barr RJ, Truong T, Holcombe RF. Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol Pathol 2003;56:280-5.
22. Straume O, Akslen LA. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 1996;78:1211-9.
23. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003;9:250-6.
24. Straume D, Salvesen HB, Akslen LA. Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol 1999;15:595-9.
25. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000;6:1845-53.
26. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/ EphA2 on melanoma progression. Am J Pathol 2002; 160:1009-19.
27. Straume O, Akslen LA. Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001;159:223-35.
28. Bachmann IM, Straume O, Akslen LA. Altered expression of cell cycle regulators cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol 2004; 25:1559-65.
29. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
30. Clark WH, Jr., From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-27.
31. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
32. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158: 1245-51.
33. Nocito A, Bubendorf L, MariaTinner E, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-57.
34. Aas T, Borresen AL, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2:811-4.
35. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997;74: 535-9.
36. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA. P-cadherin expression in breast carcinoma indicates poor survival. Cancer 1999;86: 1263-72.
37. Gamallo C, Moreno-Bueno G, Sarrio D, Calero F, Hardisson D, Palacios J. The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol 2001;14:650-4.
38. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004;22:1242-52.
39. Hsu M, Andl T, Li G, Meinkoth JL, Herlyn M. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci 2000;113:1535-42.
40. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001; 61:3819-25.
41. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509-12.
42. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398:422-6.
43. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-91.
44. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. β-Catenin expression pattern in stage I and II ovarian carcinomas: relationship with β-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155: 527-36.
45. Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC. Expression of mutant nuclear β-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001;193: 95-101.
46. Iozzo RV, Eichstetter I, Danielson KG. Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res 1995;55:3495-9.
47. Crnogorac-Jurcevic T, Efthimiou E, Capelli P, et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001;20:7437-46.
48. Olson DJ, Gibo DM, Saggers G, Debinski W, Kumar R. Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a. Cell Growth Differ 1997;8:417-23.
49. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J Cell Biol 2003;162:899-908.
50. Itoh K, Brott BK, Bae GU, Ratcliffe MJ, Sokol SY. Nuclear localization is required for Dishevelled function in Wnt/β-catenin signaling. J Biol 2005;4:3.
51. Theisen H, Purcell J, Bennett M, Kansagara D, Syed A, Marsh JL. dishevelled is required during wingless signaling to establish both cell polarity and cell identity. Development 1994;120:347-60.
52. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSKSβ to the APC-β-catenin complex and regulation of complex assembly. Science 1996;272:1023-6.
53. Delrieu I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett 2000; 468:6-10.